Sunday 18 October 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE
Insiders bought in the last twelve months.
18.71
0.84
−4.30%
Follow BRVE
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
13.63 | 8.11 | 17.03 | — |
+1 more quarter Free account |
Net Debt/EBITDA |
7.72 | 5.34 | 0.00 | 0.00 | |
Debt/Assets |
0.16% | 0.36% | 0.00% | — | |
Debt/Equity |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.91 | 0.36 | — | 0.00 | |
Capex/Depreciation |
2.67 | (18.00) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Free Cash Flow per Share |
(2.29) | (0.76) | — | 0.00 | |
Cash per Share |
16.59 | 11.74 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(12.96) | (11.42) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
(12.96) | (11.42) | 0.00 | 0.00 | |
Free Cash Flow |
(16.94) | (5.22) | — | 0.00 | |
Working Capital |
114.39 | 71.07 | 84.04 | — | |
Capital Expenditures |
0.01 | (0.04) | — | — | |
Net Current Asset Value |
(99.42) | (79.20) | (65.94) | — | |
| Other line items | |||||
Quick Ratio |
13.56 | 8.06 | 17.01 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(2.29) | (0.76) | — | 0.00 | |
Capex per Share |
0.00 | (0.01) | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 1 Oct 2026